Vaz SC, Oliveira F, Herrmann K, Veit-Haibach P. Nuclear medicine and molecular imaging advances in the 21st century[J]. Br J Radiol. 2020;93(1110):20200095.

Article  PubMed  PubMed Central  Google Scholar 

Gomes Marin JF, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, Barbosa FG, et al. Theranostics in Nuclear Medicine: emerging and re-emerging Integrated Imaging and therapies in the era of Precision Oncology[J]. Radiographics. 2020;40(6):1715–40.

Article  PubMed  Google Scholar 

Chakravarty R, Goel S, Cai W. Nanobody: the magic bullet for molecular imaging?[J]. Theranostics. 2014;4(4):386–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panikar SS, Banu N, Haramati J, Del Toro-Arreola S, Riera Leal A, Salas P. Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy[J]. J Control Release. 2021;334:389–412.

Article  CAS  PubMed  Google Scholar 

Ma J, Xu X, Fu C, Xia P, Tian M, Zheng L, et al. CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin[J]. Biomater Res. 2022;26(1):64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains[J]. Nature. 1993;363(6428):446–8.

Article  CAS  PubMed  Google Scholar 

Piramoon M, Khodadust F, Hosseinimehr SJ. Radiolabeled nanobodies for tumor targeting: from bioengineering to imaging and therapy[J]. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188529.

Article  CAS  PubMed  Google Scholar 

Muyldermans S. Nanobodies: natural single-domain antibodies[J]. Annu Rev Biochem. 2013;82:775–97.

Article  CAS  PubMed  Google Scholar 

Yang E, Liu Q, Huang G, Liu J, Wei W. Engineering nanobodies for next-generation molecular imaging[J]. Drug Discov Today. 2022;27(6):1622–38.

Article  CAS  PubMed  Google Scholar 

Asgari R, Vaisi-Raygani A, Aleagha MSE, Mohammadi P, Bakhtiari M, Arghiani N. CD147 and MMPs as key factors in physiological and pathological processes[J]. Biomed Pharmacother. 2023;157:113983.

Article  CAS  PubMed  Google Scholar 

Nyalali AMK, Leonard AU, Xu Y, Li H, Zhou J, Zhang X, et al. CD147: an integral and potential molecule to abrogate hallmarks of cancer[J]. Front Oncol. 2023;13:1238051.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu B, Zhang Y, Wu K, Wang L, Jiang Y, Chen W, et al. CD147 promotes progression of head and neck squamous cell carcinoma via NF-kappa B signaling[J]. J Cell Mol Med. 2019;23(2):954–66.

Article  CAS  PubMed  Google Scholar 

Meng Y, Fan XY, Yang LJ, Xu BQ, He D, Xu Z, et al. Detachment activated CyPA/CD147 induces Cancer Stem Cell potential in non-stem breast Cancer Cells[J]. Front Cell Dev Biol. 2020;8:543856.

Article  PubMed  PubMed Central  Google Scholar 

Lv Y, Wang T, Fan J, Zhang Z, Zhang J, Xu C, et al. The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147(+) breast cancer stem cells[J]. Tumour Biol. 2017;39(4):1010428317695927.

Article  PubMed  Google Scholar 

Ke X, Chen Y, Wang P, Xing J, Chen Z. Upregulation of CD147 protects hepatocellular carcinoma cell from apoptosis through glycolytic switch via HIF-1 and MCT-4 under hypoxia[J]. Hepatol Int. 2014;8(3):405–14.

Article  PubMed  Google Scholar 

Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair[J]. Biochimie. 2005;87(3–4):361–8.

Article  CAS  PubMed  Google Scholar 

Jiang Y, Liang R, Li L, Guan J. Studies on the effect and mechanism of CD147 on melanoma stem cells[J]. Allergol Immunopathol (Madr). 2024;52(1):71–8.

Article  PubMed  Google Scholar 

Zhang W, Liu H, Jiang J, Yang Y, Wang W, Jia Z. Expression of CD147 after neoadjuvant chemotherapy and its relationship with prognosis in patients with triple negative breast cancer[J]. Am J Transl Res. 2022;14(5):2952–61.

CAS  PubMed  PubMed Central  Google Scholar 

Liu H, Xu XF, Zhao Y, Tang MC, Zhou YQ, Gao FH. NS-398 promotes pancreatic cancer cell invasion by CD147 and MMP-2 via the activation of P38[J]. Mol Med Rep. 2016;13(3):2208–14.

Article  CAS  PubMed  Google Scholar 

Li J, Huang Q, Long X, Zhang J, Huang X, Aa J, et al. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways[J]. J Hepatol. 2015;63(6):1378–89.

Article  CAS  PubMed  Google Scholar 

Zhang J, Wang Z, Zhang X, Dai Z, Zhi-Peng W, Yu J, et al. Large-scale single-cell and bulk sequencing analyses reveal the Prognostic Value and Immune aspects of CD147 in Pan-Cancer[J]. Front Immunol. 2022;13:810471.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation[J]. Hepatology. 2007;45(2):269–76.

Article  CAS  PubMed  Google Scholar 

Li J, Xing J, Yang Y, Liu J, Wang W, Xia Y, et al. Adjuvant (131)I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol. 2020;5(6):548–60.

Article  PubMed  Google Scholar 

Ma XK, Liu TL, Ren YN, Ma XP, Yao Y, Hou XG, et al. (124)I-labeled anti-CD147 antibody for noninvasive detection of CD147-positive pan-cancers: construction and preclinical studies[J]. Acta Pharmacol Sin. 2024;45(2):436–48.

Article  CAS  PubMed  Google Scholar 

Li R, Zhu X, Zhou P, Qiao Y, Li Y, Xu Y, et al. Generation of a High-Affinity Nanobody against CD147 for Tumor Targeting and Therapeutic Efficacy through conjugating Doxorubicin[J]. Front Immunol. 2022;13:852700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue][J]. Pathologe. 1987;8(3):138–40.

CAS  PubMed  Google Scholar 

Garland M, Yim JJ, Bogyo M. A Bright Future for Precision Medicine: advances in fluorescent Chemical Probe Design and their clinical Application[J]. Cell Chem Biol. 2016;23(1):122–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sugyo A, Tsuji AB, Sudo H, Nagatsu K, Koizumi M, Ukai Y, et al. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer[J]. PLoS ONE. 2013;8(4):e61230.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu T, Huang H, Sheng Y, Shi H, Min Y, Liu Y. Transglutaminase mediated PEGylation of nanobodies for targeted nano-drug delivery[J]. J Mater Chem B. 2018;6(7):1011–17.

Article  CAS  PubMed  Google Scholar 

Verhaar ER, Woodham AW, Ploegh HL. Nanobodies in cancer[J]. Semin Immunol. 2021;52:101425.

Article  CAS  PubMed  Google Scholar 

Krasniqi A, D’Huyvetter M, Devoogdt N, Frejd FY, Sörensen J, Orlova A, et al. Same-day imaging using small proteins: clinical experience and translational prospects in Oncology[J]. J Nucl Med. 2018;59(6):885–91.